Abrysvo is indicated for:• Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. • Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.